The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction

Author(s): Maria Scherma, Paola Fadda, Bernard Le Foll, Benoit Forget, Walter Fratta, Steven R. Goldberg, Gianluigi Tanda

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 7 , Issue 5 , 2008

Become EABM
Become Reviewer
Call for Editor


Tobacco addiction is one of the leading preventable causes of mortality in the world and nicotine appears to be the main critical psychoactive component in establishing and maintaining tobacco dependence. Several lines of evidence suggest that the rewarding effects of nicotine, which underlie its abuse potential, can be modulated by manipulating the endocannabinoid system. For example, pharmacological blockade or genetic deletion of cannabinoid CB1 receptors reduces or eliminates many behavioral and neurochemical effects of nicotine that are related to its addictive potential. This review will focus on the recently published literature about the role of the endocannabinoid system in nicotine addiction and on the endocannabinoid system as a novel molecular target for the discovery of medications for tobacco dependence.

Keywords: Addiction, tobacco dependence, nicotine, endocannabinoid system, CB1 receptors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [468 - 481]
Pages: 14
DOI: 10.2174/187152708786927859
Price: $65

Article Metrics

PDF: 3